Cingulate Inc. (CING) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Cingulate Inc. is a pre-revenue biopharmaceutical company developing once-daily, multi-dose tablet therapies for ADHD and anxiety using its Precision Timed Release (PTR) platform. The primary product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD, and CTx-2103 (buspirone) for anxiety. This report covers the quarterly period ended June 30, 2024. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3.21) million | $(6.62) million | $(6.18) million | $(10.62) million |
| Operating Loss | $(3.21) million | $(6.36) million | $(6.15) million | $(10.21) million |
| R&D Expenses | $(1.88) million | $(4.46) million | $(3.69) million | $(6.58) million |
| G&A Expenses | $(1.33) million | $(1.91) million | $(2.47) million | $(3.63) million |
| Cash & Equivalents (End of Period) | $0.38 million | $0.35 million | $0.38 million | $0.35 million |
| Accumulated Deficit | $(99.13) million | $(80.03) million | $(99.13) million | $(80.03) million |
| Debt (Note Payable) | $0 | $3.0 million | $0 | $3.0 million |
Note: The company had no debt outstanding as of June 30, 2024, following the conversion of a related-party note to equity in early 2024.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by 51.5% in Q2 2024 compared to Q2 2023. This was driven by a 57.8% decrease in R&D expenses and a 30.5% decrease in G&A expenses.
- Cost Containment: Management implemented cost-saving measures in late 2023, including headcount reductions and salary reductions ranging from 5% to 55% for all employees.
- Clinical Activity: R&D costs declined significantly as the company completed enrollment in two Phase 3 studies for CTx-1301 in late 2023. Current activities focus on data analysis and regulatory preparation rather than active clinical trials.
- Debt Elimination: The $3.0 million related-party note payable outstanding at the end of 2023 was fully converted to pre-funded warrants and subsequently to common stock in 2024, eliminating interest expense.
- Capital Raising: The company raised approximately $11.0 million in net proceeds from financing activities in the first six months of 2024, including a public offering, ATM sales, and a Lincoln Park agreement.
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern for one year. Management estimates a need for an additional $12-13 million to fund operations through the targeted NDA submission for CTx-1301 in the first half of 2025.
- Recent Capital Events: Subsequent to June 30, 2024, the company closed a Warrant Inducement on July 1, 2024, raising approximately $1.6 million. Additionally, a one-for-twelve reverse stock split was completed on August 9, 2024.
- Nasdaq Compliance: The company is under a discretionary panel monitor until May 2025 following a delisting threat for failing to meet the Minimum Bid Price Rule ($1.00). The August 2024 reverse split was executed to regain compliance.
- Development Timeline: The company targets an NDA submission for CTx-1301 in H1 2025. Development of CTx-1302 and CTx-2103 is pending additional capital resources.
- Strategic Partnerships: The company is actively seeking a strategic pharmaceutical partnership to license CTx-1301. A joint commercialization agreement with Indegene exists as a fee-for-service backup option.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.6 million raised in July 2024 against the stated $12-13 million funding gap for the 2025 NDA submission.
- Nasdaq Status: Confirm the company's continued compliance with the Minimum Bid Price Rule following the August 9, 2024 reverse stock split.
- Dilution Impact: Assess the dilution from the recent warrant inducement, reverse stock split, and ongoing ATM/Lincoln Park sales on existing shareholders.
- Clinical Milestones: Monitor the timeline for the Phase 1 food effect study for CTx-1301 and the subsequent NDA submission in H1 2025.
- Going Concern Resolution: Watch for announcements regarding additional equity raises, debt financing, or strategic partnerships required to resolve the going concern uncertainty.